“drugs” Archives

in
Entry Author Date Location
FDA Approves Houston Biotech Lexicon’s Carcinoid Syndrome Diarrhea Drug 02/28/17 Texas
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
BioCrossroads Report: Steady Growth for Life Sciences in Indiana 02/24/17 Indiana
Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M 02/22/17 New York
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs 02/14/17 New York
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
No Details Yet, But Amgen Touts Success in Big Heart Drug Study 02/02/17 San Francisco
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof 02/02/17 Boston
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Texas Roundup: Comey at SXSW, CTAN, RealCo, Fannin, “Trump and Dump” 01/30/17 Texas
Polish Subsidiary of San Antonio Firm Gets $4.6M for Endometriosis 01/26/17 Texas
Just Four Months After Series A, Delinia Sells to Celgene For $300M 01/26/17 Boston
Purdue’s On Target Laboratories Lights Up the Fight Against Cancer 01/25/17 Indiana
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval 01/24/17 Boston
Texas Roundup: Azaya, StemBioSys, Next Coast, Querium, Favor, MacroFab 01/23/17 Texas
With Another Migraine Drug Bet, Lilly Snaps Up CoLucid For $960M 01/18/17 Indiana
Texas Roundup: EnergyFunders, Neal Murthy, Xenex, Xeris, LiveOak 01/17/17 Texas
Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round 01/10/17 Texas
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M 01/08/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
RaNA Expands, Joins Messenger RNA Drug Race With Shire Deal 01/04/17 Boston
Inotek’s Glaucoma Drug Flunks in First Phase 3 Test, Shares Crumble 01/03/17 Boston
Watching for NIH Innovation in 2017—and Drug Pricing, Trade Deals 01/02/17 San Diego
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Texas Roundup: “1st & Future,” “Pink Tank” Pitch Contests, & More 12/23/16 Texas
Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push 12/20/16 Boston
Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug 12/19/16 Boulder/Denver
Page 3 of 94 « previous page · next page »